Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This ...

1 Laboratory of Thromboinflammation, Nasonova Research Institute of Rheumatology, Russian Federation 2 Laboratories of biomedical research methods, Moscow Regional Clinical Research Institute named ...

Objectives To evaluate the time course of clinical response following anifrolumab treatment in patients with SLE. Methods A post hoc analysis was conducted using pooled data from phase III, randomised ...

Background The course and evolution of the SLE depends on the affected organ, adherence to treatment and accumulated organ damage, but ethnicity plays a fundamental role, leading to worse results in ...

Objectives Cardiovascular disease (CVD) is a leading cause of death in SLE. Coronary artery calcium (CAC) scores predict CVD events, independent of traditional risk factors. Patients with SLE aged >45 ...

1 Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Chinese Medicine, Beijing, China Objective Celastrol is a bioactive constituent extracted from ...

Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 ...

Purpose Peptidylarginine deiminase (PAD) 1–4 and PAD6 are responsible for protein citrullination. PAD4 is highly expressed in neutrophils and is essential for NETosis, which has been implicated in the ...